Stephens Investment Management Group LLC Sells 7,752 Shares of IDEXX Laboratories, Inc. $IDXX

Stephens Investment Management Group LLC cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.5% in the third quarter, Holdings Channel.com reports. The fund owned 95,601 shares of the company’s stock after selling 7,752 shares during the quarter. Stephens Investment Management Group LLC’s holdings in IDEXX Laboratories were worth $61,079,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. STF Management LP raised its holdings in shares of IDEXX Laboratories by 1.3% during the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares in the last quarter. Clearstead Trust LLC increased its position in IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after buying an additional 16 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after buying an additional 16 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after buying an additional 17 shares during the last quarter. Finally, Stratos Wealth Partners LTD. boosted its stake in shares of IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after acquiring an additional 18 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.5%

IDXX opened at $715.37 on Friday. The business has a 50 day moving average of $706.72 and a 200-day moving average of $649.45. The stock has a market capitalization of $57.12 billion, a price-to-earnings ratio of 56.73, a P/E/G ratio of 3.81 and a beta of 1.67. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. IDEXX Laboratories’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. UBS Group increased their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Barclays initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 price objective for the company. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Finally, Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $763.50.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.